⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.
Dexrazoxane
دکسرازوکسان
🧪 VariousAnthracycline cardioprotectant
🤰 Pregnancy:Dangerous / avoid🤱 Breastfeeding:Use with caution👶 Children:Safety not established👴 Older adults:Use with caution 🇮🇷 Registered in Iran⛔ 1 contraindications 🇺🇸 FDA approved generic (ANDA) ANDA200752ATC V03AF02
Market / country: 🇺🇸 USA
Zinecard (US)
🧮 Dose calculator
Breast cancer (hormonal therapy) · Regimen source: FDA Dexrazoxane · 2.1FDA Dexrazoxane · 2.2
⛔ Dose = 10 × the doxorubicin dose (mg/m²); slow push or rapid drip; give doxorubicin within 30 min after it ends (never before). CrCl <40: 5:1 ratio. FDA Dexrazoxane · 2.1FDA Dexrazoxane · 2.2
🛡️ Safety & information
Contraindications
- ⛔ Do not use with non-anthracycline regimens. FDA Dexrazoxane · 4
Warnings
- • Added myelosuppression; cardiac toxicity still possible; secondary malignancy; embryo-fetal toxicity. FDA Dexrazoxane · 5
Formulations
- 250 mg vial — powder for injection 🇺🇸 USA FDA Dexrazoxane · 3
👥 Special populations
- 🤰 PregnancyDangerous / avoid
Label: can cause fetal harm. Dangerous in pregnancy. FDA Dexrazoxane · 8.1
“Risk Summary Dexrazoxane can cause fetal harm when administered to pregnant women.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Dexrazoxane · 8.3
“Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from dexrazoxane, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Dexrazoxane · 8.4
“The safety and effectiveness of dexrazoxane in pediatric patients have not been established [see Warnings and Precautions (5.4) ] .”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Dexrazoxane · 8.5
“In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA200752
- DailyMed (FDA label)FDA Dexrazoxane
- MedlinePlus (NIH)Dexrazoxane Injection
- WHO ATC/DDDV03AF02
- Darooyab (Iran)Dexrazoxane
🇮🇷 Registered in Iran Darooyab · G-1947/Dexrazoxane
Dosage forms with Iranian generic codes, per Darooyab.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Dexrazoxane · 3FDA Dexrazoxane · 2.1FDA Dexrazoxane · 2.2FDA Dexrazoxane · 4FDA Dexrazoxane · 5FDA Dexrazoxane · SPL approval / marketing categoryFDA Dexrazoxane · 8.1FDA Dexrazoxane · 8.3FDA Dexrazoxane · 8.4FDA Dexrazoxane · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1947/Dexrazoxane
- Clinical review⚠ Unverified